Slope and Velocity Clinical Research Partner to Standardize Inventory Management Across 70+ Sites
核心洞察
Slope (搜索)'s premium inventory management solution has been deployed across Velocity Clinical Research (搜索)'s entire network of 70+ sites in the United States and Europe.
The partnership enables Velocity to leverage real-time trial equipment data to inform study feasibility decisions and operational readiness across its network.
Slope (搜索)'s platform had already been independently adopted at 31 Velocity sites prior to the formal partnership, demonstrating grassroots confidence in the solution.
Slope (搜索), an end-to-end vendor-agnostic software provider for managing clinical inventory and biospecimens, and Velocity Clinical Research (搜索), the world's largest organization of fully-owned and integrated clinical research sites, announced a strategic partnership that has resulted in the comprehensive roll-out of Slope's premium inventory management solution across Velocity's network of more than 70 sites spanning the United States and Europe. The deployment, announced June 23, 2026, is already enabling Velocity to harness trial equipment data to inform study feasibility decisions across its network.
The partnership marks a significant milestone for both organizations. Slope (搜索) further solidifies its position in the clinical research space by standardizing its industry-leading clinical inventory management solution with a premier research site network, while Velocity gains access to an innovative platform that has already been adopted by over 2,400 research sites globally across more than two dozen countries.
Grassroots Adoption Paved the Way
Prior to the formal partnership, Slope (搜索)'s base inventory management solution had already been independently adopted at 31 of Velocity's sites. According to Nicholas Spittal, Chief Operations Officer at Velocity, this organic uptake provided critical validation. "This grassroots adoption gave confidence that Slope is easy to use and already providing added value for running efficient sites," Spittal said. "With real-time visibility into study equipment and clinical supplies across all of Velocity, we can now make faster, better-informed decisions about operational readiness, prioritization, and allocation of work. We're already leveraging this data to support our study feasibility and quality assurance processes."
Addressing a Critical Industry Pain Point
Rust Felix, Co-founder and CEO at Slope (搜索), emphasized the company's site-first philosophy. "From its inception, Slope has championed research sites first and foremost," Felix said. "Research sites are on the front lines of clinical trials, playing the most challenging and critical role in bringing new therapies to patients. When we help them work more efficiently and reduce their administrative burden, the entire clinical research ecosystem benefits."
Felix added that the partnership is already fueling joint efforts to address "one of the industry's most significant pain points — managing the inventory and study equipment that are essential to running clinical trials."
Operational Impact and Future Expectations
By integrating Slope (搜索)'s equipment data into its broader operational infrastructure, Velocity can now determine at a glance whether a site is operationally ready to support a new study, reducing the time and guesswork involved in site selection. Slope's platform has demonstrated measurable results across its user base, including a 71% average reduction in lab kit waste, 98% site adoption on sponsor-contracted trials, and up to 98% fewer lab queries.
As the partnership continues to scale, both organizations expect these operational gains to translate into faster study startup times, reduced supply waste, and a stronger competitive position for Velocity's sites in attracting new trials. The collaboration underscores a growing industry trend toward leveraging technology-enabled solutions to streamline clinical trial operations and accelerate the delivery of new therapies to patients.